RxSight, Inc. Q3 FY2026 earnings call

Strategic Priorities: Management has identified three core priorities: strengthening the U.S. LAL commercial business, advancing the next-generation adjustable lens pipeline, and executing on the collaboration with Alcon.

Commercial Leadership & Expansion: Significant progress has been made in enhancing commercial capabilities. New appointments include Taryn Conway as Chief Commercial Officer and Frank Shields as EVP of Sales and Commercial Strategy. The U.S. sales force has nearly doubled in size to enable higher-frequency engagement with physicians and deeper integration into practice workflows.

Physician Engagement & Adoption: CEO Aziz Mottiwala emphasized strong physician belief in LAL outcomes, particularly for post-refractive surgery patients. The strategy focuses on scaling successful models from top-utilizing practices to the broader install base through better education, workflow integration, and peer-to-peer advocacy.

Restructuring & Efficiency: A comprehensive restructuring involving manufacturing, corporate functions, and international operations was completed. This is expected to generate meaningful cost savings in the base business starting in 2027, allowing for continued investment in strategic initiatives like the Alcon partnership and next-gen pipeline.

Alcon Collaboration: The partnership with Alcon has passed the initial 120-day milestone, solidifying upfront payments. Teams are aligned and making robust progress toward bringing adjustability to a broader premium IOL market.

Next-Gen Pipeline: Development is focused on innovations that expand the patient population eligible for adjustability, reduce clinical workflow visits, and enhance surgical ease.

Total company revenue for Q3 2026 was $24.6 million, a 19% decline from $30.3 million in the prior year period. The Light-Adjustable Lens (LAL) procedure segment generated $22.8 million in revenue, accounting for approximately 92.7% of total revenue. LAL procedure volume declined 11% to 23,128 units from 26,045 units in the prior year. The remaining revenue ($1.8 million) came from Lens Delivery Device (LDD) and service revenues. Gross margin decreased to 73.6% from 79.9% in the prior year, primarily due to increased inventory reserves, partially offset by favorable product mix.

The company did not provide formal full-year 2026 financial guidance during this call.

Management intends to resume providing financial guidance for 2027 when reporting fourth-quarter results early next year.

For Q4 2026, management anticipates LAL sales to be in line with Q2 levels, reflecting mid-to-high single-digit sequential growth, driven by improved seasonality compared to Q3.

Management expects operating expenses (OpEx) to decrease significantly in 2027 versus 2026 due to restructuring savings, despite incremental investments in the sales team and R&D.

Competitive Pressure: Ongoing competitive pressures from new IOL launches are impacting utilization, largely due to competitors offering free product sampling and trialing lenses.

Operational Disruption: Recent internal restructuring, including territory remapping and significant sales force expansion, has caused near-term disruption and reduced field presence.

Revenue Decline: Total revenue and LAL volumes have declined year-over-year, reflecting both competitive headwinds and execution challenges.

Execution Risk: Success depends on the effective onboarding of new sales staff and the consistent application of new commercial strategies across the entire customer base.

Q: Analysts asked about the compounding factors behind the Q3 performance step-down compared to Q2, specifically regarding competitive trends and post-refractive patient focus.

A: Management attributed the decline to three factors: seasonal softness in Q3, continued competitive pressure from free product sampling affecting utilization, and internal disruption from the Salesforce expansion and restructuring. While acknowledging the weakness, they noted optimism as top-performing surgeons continue to grow, indicating that pockets of success can be scaled if commercial levers are applied consistently across the broader base.